Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Abeona Therapeutics (ABEO) Other Non Operating Income: 2012-2014

Historic Other Non Operating Income for Abeona Therapeutics (ABEO) over the last 3 years, with Dec 2014 value amounting to -$11.3 million.

  • Abeona Therapeutics' Other Non Operating Income fell 2351.19% to -$11.3 million in Q4 2014 from the same period last year, while for Dec 2014 it was -$23.1 million, marking a year-over-year decrease of 388.51%. This contributed to the annual value of -$23.1 million for FY2014, which is 388.51% down from last year.
  • Per Abeona Therapeutics' latest filing, its Other Non Operating Income stood at -$11.3 million for Q4 2014, which was down 1,514.29% from -$700,000 recorded in Q3 2014.
  • Abeona Therapeutics' Other Non Operating Income's 5-year high stood at $21.0 million during Q4 2012, with a 5-year trough of -$13.9 million in Q3 2012.
  • Over the past 3 years, Abeona Therapeutics' median Other Non Operating Income value was -$580,500 (recorded in 2013), while the average stood at -$1.7 million.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first surged by 294.31% in 2013, then crashed by 2,351.19% in 2014.
  • Over the past 3 years, Abeona Therapeutics' Other Non Operating Income (Quarterly) stood at $21.0 million in 2012, then crashed by 102.20% to -$461,000 in 2013, then plummeted by 2,351.19% to -$11.3 million in 2014.
  • Its Other Non Operating Income was -$11.3 million in Q4 2014, compared to -$700,000 in Q3 2014 and -$11.7 million in Q2 2014.